Vitamin D Analogs Regulate the Vitamin D System and Cell Viability in Ovarian Cancer Cells

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 Jan 11

PMID 35008598

Authors

Karina Piatek

Andrzej Kutner

Dan Cacsire Castillo-Tong

Teresa Manhardt

Nadja Kupper

Urszula Nowak

Michal Chodynski

Ewa Marcinkowska

Eniko Kallay

Martin Schepelmann

Affiliations

Soon will be listed here.

Abstract

Background: Ovarian cancer (OC) is one of the most lethal cancers in women. The active form of vitamin D, 1,25-dihydroxyvitamin D (1,25D, calcitriol) has anticancer activity in several cancers, including ovarian cancer, but the required pharmacological doses may cause hypercalcemia. We hypothesized that newly developed, low calcemic, vitamin D analogs (an1,25Ds) may be used as anticancer agents instead of calcitriol in ovarian cancer cells.

Methods: We used two patient-derived high-grade serous ovarian cancer (HGSOC) cell lines with low (13781) and high (14433) mRNA expression levels of the gene encoding 1,25-dihydroxyvitamin D 24-hydroxylase , one of the main target genes of calcitriol. We tested the effect of calcitriol and four structurally related series of an1,25Ds (PRI-1906, PRI-1907, PRI-5201, PRI-5202) on cell number, viability, the expression of , and the vitamin D receptor (VDR).

Results: mRNA expression increased in a concentration-dependent manner after treatment with all compounds. In both cell lines, after 4 h, PRI-5202 was the most potent analog (in 13781 cells: EC = 2.98 ± 1.10 nmol/L, in 14433 cells: EC = 0.92 ± 0.20 nmol/L), while PRI-1907 was the least active one (in 13781 cells: EC = n/d, in 14433 cells: EC = n/d). This difference among the analogs disappeared after 5 days of treatment. The 13781 cells were more sensitive to the an1,25Ds compared with 14433 cells. The an1,25Ds increased nuclear VDR levels and reduced cell viability, but only in the 13781 cell line.

Conclusions: The an1,25Ds had different potencies in the HGSOC cell lines and their efficacy in increasing expression was cell line- and chemical structure-dependent. Therefore, choosing sensitive cancer cell lines and further optimization of the analogs' structure might lead to new treatment options against ovarian cancer.

Citing Articles

Vitamin D in Cancer Prevention and Treatment: A Review of Epidemiological, Preclinical, and Cellular Studies.

Dallavalasa S, Tulimilli S, Bettada V, Karnik M, Uthaiah C, Anantharaju P Cancers (Basel). 2024; 16(18).

PMID: 39335182 PMC: 11430526. DOI: 10.3390/cancers16183211.

Nuclear receptors in ovarian cancer: changing paradigms in cancer therapeutics.

Sajeev A, BharathwajChetty B, Manickasamy M, AlQahtani M, Abbas M, Shakibaei M Front Oncol. 2024; 14:1383939.

PMID: 39077471 PMC: 11284039. DOI: 10.3389/fonc.2024.1383939.

Structure and the Anticancer Activity of Vitamin D Receptor Agonists.

Powala A, Zolek T, Brown G, Kutner A Int J Mol Sci. 2024; 25(12).

PMID: 38928329 PMC: 11203455. DOI: 10.3390/ijms25126624.

Vitamin D3 regulates NSUN2 expression and inhibits melanoma cell proliferation and migration.

Wang L, Zhang Q, Wang J, Lu H, Zeng W, Zhang T Mol Divers. 2023; 28(5):2863-2874.

PMID: 37688740 DOI: 10.1007/s11030-023-10720-9.

Value of plasma vitamin D level and nomogram model for predicting the prognosis of patients with small cell lung cancer treated with platinum plus etoposide as first-line chemotherapy.

Zhang X, Li W, Liu Y, Xu L, Wang X, Feng X Am J Transl Res. 2022; 14(11):7771-7781.

PMID: 36505322 PMC: 9730104.

References

Arai M, Kittaka A . Novel 2-alkyl-1alpha,25-dihydroxy-19-norvitamin D3: efficient synthesis with Julia olefination, evaluation of biological activity and development of new analyzing system for co-activator recruitment. Anticancer Res. 2006; 26(4A):2621-31. View

Hobaus J, Hummel D, Thiem U, Fetahu I, Aggarwal A, Mullauer L . Increased copy-number and not DNA hypomethylation causes overexpression of the candidate proto-oncogene CYP24A1 in colorectal cancer. Int J Cancer. 2013; 133(6):1380-8. PMC: 3807607. DOI: 10.1002/ijc.28143. View

Berkowska K, Corcoran A, Grudzien M, Jakuszak A, Chodynski M, Kutner A . Investigating the Role of VDR and Megalin in Semi-Selectivity of Side-Chain Modified 19- Analogs of Vitamin D. Int J Mol Sci. 2019; 20(17). PMC: 6747128. DOI: 10.3390/ijms20174183. View

Roff A, Wilson R . A novel SNP in a vitamin D response element of the CYP24A1 promoter reduces protein binding, transactivation, and gene expression. J Steroid Biochem Mol Biol. 2008; 112(1-3):47-54. PMC: 2749287. DOI: 10.1016/j.jsbmb.2008.08.009. View

Nadkarni S, Chodynski M, Corcoran A, Marcinkowska E, Brown G, Kutner A . Double point modified analogs of vitamin d as potent activators of vitamin D receptor. Curr Pharm Des. 2014; 21(13):1741-63. DOI: 10.2174/1381612821666141205125113. View

Vaisanen S, Dunlop T, Sinkkonen L, Frank C, Carlberg C . Spatio-temporal activation of chromatin on the human CYP24 gene promoter in the presence of 1alpha,25-Dihydroxyvitamin D3. J Mol Biol. 2005; 350(1):65-77. DOI: 10.1016/j.jmb.2005.04.057. View

Christakos S, Dhawan P, Verstuyf A, Verlinden L, Carmeliet G . Vitamin D: Metabolism, Molecular Mechanism of Action, and Pleiotropic Effects. Physiol Rev. 2015; 96(1):365-408. PMC: 4839493. DOI: 10.1152/physrev.00014.2015. View

Baurska H, Marchwicka A, Klopot A, Kutner A, Marcinkowska E . Studies on the mechanisms of superagonistic pro-differentiating activities of side-chain modified analogs of vitamin D2. Oncol Rep. 2012; 28(3):1110-6. DOI: 10.3892/or.2012.1886. View

Nachliely M, Trachtenberg A, Khalfin B, Nalbandyan K, Cohen-Lahav M, Yasuda K . Dimethyl fumarate and vitamin D derivatives cooperatively enhance VDR and Nrf2 signaling in differentiating AML cells in vitro and inhibit leukemia progression in a xenograft mouse model. J Steroid Biochem Mol Biol. 2018; 188:8-16. DOI: 10.1016/j.jsbmb.2018.11.017. View

10.

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

11.

Baurska H, Kielbinski M, Biecek P, Haus O, Jazwiec B, Kutner A . Monocytic differentiation induced by side-chain modified analogs of vitamin D in ex vivo cells from patients with acute myeloid leukemia. Leuk Res. 2014; 38(5):638-47. DOI: 10.1016/j.leukres.2014.03.009. View

12.

Wietrzyk J, Nevozhay D, Milczarek M, Filip B, Kutner A . Toxicity and antitumor activity of the vitamin D analogs PRI-1906 and PRI-1907 in combined treatment with cyclophosphamide in a mouse mammary cancer model. Cancer Chemother Pharmacol. 2008; 62(5):787-97. DOI: 10.1007/s00280-007-0666-6. View

13.

Guo H, Guo J, Xie W, Yuan L, Sheng X . The role of vitamin D in ovarian cancer: epidemiology, molecular mechanism and prevention. J Ovarian Res. 2018; 11(1):71. PMC: 6114234. DOI: 10.1186/s13048-018-0443-7. View

14.

Ong J, Cuellar-Partida G, Lu Y, Fasching P, Hein A, Burghaus S . Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. Int J Epidemiol. 2016; 45(5):1619-1630. PMC: 5100621. DOI: 10.1093/ije/dyw207. View

15.

Trump D, Deeb K, Johnson C . Vitamin D: considerations in the continued development as an agent for cancer prevention and therapy. Cancer J. 2010; 16(1):1-9. PMC: 2857702. DOI: 10.1097/PPO.0b013e3181c51ee6. View

16.

Feldman D, Krishnan A, Swami S, Giovannucci E, Feldman B . The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer. 2014; 14(5):342-57. DOI: 10.1038/nrc3691. View

17.

Kreuzinger C, von der Decken I, Wolf A, Gamperl M, Koller J, Karacs J . Patient-derived cell line models revealed therapeutic targets and molecular mechanisms underlying disease progression of high grade serous ovarian cancer. Cancer Lett. 2019; 459:1-12. DOI: 10.1016/j.canlet.2019.05.032. View

18.

Zhang X, Jiang F, Li P, Li C, Ma Q, Nicosia S . Growth suppression of ovarian cancer xenografts in nude mice by vitamin D analogue EB1089. Clin Cancer Res. 2005; 11(1):323-8. View

19.

Fernandez-Barral A, Bustamante-Madrid P, Ferrer-Mayorga G, Barbachano A, Larriba M, Munoz A . Vitamin D Effects on Cell Differentiation and Stemness in Cancer. Cancers (Basel). 2020; 12(9). PMC: 7563562. DOI: 10.3390/cancers12092413. View

20.

Baurska H, Klopot A, Kielbinski M, Chrobak A, Wijas E, Kutner A . Structure-function analysis of vitamin D(2) analogs as potential inducers of leukemia differentiation and inhibitors of prostate cancer proliferation. J Steroid Biochem Mol Biol. 2011; 126(1-2):46-54. DOI: 10.1016/j.jsbmb.2011.04.006. View